US GLP-1 telehealth · dataset v2026-08-11
What a GLP-1 program actually costs, at every dose
Every other comparison quotes one number per provider. That number describes a single dose — usually the lowest — and hides what happens as you titrate. This database records the price at every dose across 37 US programs, and shows the gaps where a company never published one.
Read the shape, not just the height. A flat line is a program that charges the same at 15 mg as at 2.5 mg; a staircase is one that charges more each time your dose rises. 17 of the 27 rankable tirzepatide programs publish a price at every rung, and the other 10 leave gaps we will not fill in. Between the cheapest and the dearest sits $578 a month — $6,936 a year for the same molecule at the same dose.
The short answer, computed at this build
The cheapest all-in month-to-month compounded tirzepatide is NexLife at $169 a month, operator-stated. The lowest twelve-month cost is Trimi at $1,500 on a prepaid term. Among FDA-approved brand channels, LillyDirect (Zepbound) is lowest at $449 a month.
All-in means the medication plus every mandatory recurring fee, quoted at 10 mg/week. Compounded tirzepatide and semaglutide are not FDA-approved products.
Computed leaders
Every category below is a minimum over a column of the published dataset, recomputed at this build. No placement is assigned by a person and none can be bought — the formula and the dataset are both public, so anyone can re-run it.
Tirzepatide
Semaglutide
Only 17 of 27 tirzepatide programs publish a full ladder
The remaining 10 publish a starting price, a maintenance price, or both — and nothing in between. That gap is the difference between knowing what your third month costs and guessing at it.
NexLife charges a flat $169 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay.
Where a company has published nothing at a dose, this site leaves it blank. We do not interpolate, and we never carry a starting price forward as though it were a standing rate. The dose encyclopedia has a page per rung showing exactly who publishes what.
Where to start
The price database
All 37 programs, both medications, start and maintenance prices, memberships, twelve-month totals and capture dates.
Provider reviews
Every program assessed against its nearest priced neighbours, with what it wins and who should skip it.
Head-to-head
Every rankable pair across eight recorded dimensions, with the arithmetic shown and the two ladders overlaid.
News & analysis
The 503B decision, the pipeline and the price war — tied to what programs actually charge.
How the numbers are made
The normalisation basis, the exclusions, the scoring formula, and what we do not know.
Research journal
Evidence standing of every record, documented price changes, and the dataset's own limits.
Questions
What does all-in monthly mean on this site?
All-in monthly is the medication plus every mandatory recurring fee — membership amortised monthly, required shipping, and any consultation charge that is not optional — quoted at the maintenance dose, which is 10 mg per week for tirzepatide and 2.4 mg per week for semaglutide. It is the only figure that compares fairly across programs that bundle differently.
Why do some programs show blank doses?
Because the company has not published a price at that dose. Only 17 of 27 rankable tirzepatide programs publish a price at all six doses. We show the gap rather than interpolating a number the provider never stated.
Which program is cheapest right now?
On a month-to-month all-in basis, NexLife at $169 for tirzepatide and bmiMD at $129 for semaglutide, both compounded. These are recomputed at every build from the published dataset, so they change when prices change.
Are compounded GLP-1s FDA approved?
No. Compounded tirzepatide and semaglutide are not FDA-approved products, and the FDA does not review compounded drugs for safety, effectiveness or quality before they are dispensed. Since the tirzepatide shortage was resolved in December 2024 and the semaglutide shortage in February 2025, compounding copies of the approved products is broadly restricted.
How is this site funded?
Some outbound provider links are affiliate links that may earn a commission at no additional cost to you. Commissions are not an input to any ranking on this site, because the rankings are minima computed over a dataset you can download rather than decisions a person makes.